Optimi Health (OPTI) H.C. Wainwright 28th Annual Global Investment Conference summary

Commercial operations and product portfolio

• Currently commercial, shipping psilocybin and MDMA to Australia and Canada, with ibogaine in development and expected to be ready by year-end.

• Vertically integrated manufacturing facility in British Columbia produces naturally extracted psilocybin and synthetic MDMA capsules for clinical and commercial use.

• Products are supplied to 26 clinics in Australia, aiming to reach 100 clinics by end of 2027, and are used for treatment-resistant depression and PTSD.

• Insurance reimbursement for treatments is available in Australia, including coverage by Medibank and government support for veterans.

• Expansion plans include entering new markets as global regulatory frameworks evolve, with a focus on Canada, the U.S., and Europe.

Regulatory landscape and market dynamics

• Australia serves as a case study for successful commercialization and insurance coverage of psychedelics, with no serious adverse effects reported.

• Canada is advancing with Bill C-286 and could move faster than the U.S. in rescheduling psychedelics, supported by bipartisan interest.

• U.S. regulatory momentum is increasing, with FDA hearings scheduled and executive orders supporting psychedelic access; Schedule III rescheduling is seen as likely and beneficial.

• The company holds an FDA site license and will enter the U.S. market upon federal approval, not participating in state programs without it.

• Global inquiries and demand for ibogaine have surged following recent U.S. policy announcements.

Strategic positioning and financial highlights

• Differentiated by a regulatory-first approach and focus on manufacturing, enabling rapid entry into new markets as regulations change.

• Management team includes experienced founders and industry leaders, with significant insider investment and support from notable backers.

• Recent $15 million U.S. capital raise, with $9.2 million net proceeds and a total of $30 million raised to date, primarily from founders and insiders.

• Positioned as the only NASDAQ-listed company with natural psilocybin in-market, competing directly with synthetic-focused peers.

• Anticipates a market inflection point as regulatory changes accelerate and commercial opportunities expand globally.